Overview

Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy

Status:
Terminated

Trial end date:
2018-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of Zevalin compared with observation alone in patients who are in PET-negative complete remission after first-line R-CHOP or R-CHOP like therapy.

Phase:

Phase 3

Details

Lead Sponsor:

Spectrum Pharmaceuticals, Inc

Treatments:

Antibodies, Monoclonal
Rituximab